Metastatic Hormone-Sensitive Prostate Cancer: Difference between revisions

@@ Line 113: / Line 113: @@
 *** Median follow-up: 43 months
 *** Majority (71-76%) of patients assigned to docetaxel completed the 6 cycles
-*** SOC + '''<span style="color:#ff0000">docetaxel improved OS by 10 months</span>''' (median OS in SOC + doce 81 months vs. SOC 71 months, HR 0.78). SOC + ZA + doce has improved survival compared to SOC but no difference with SOC + doce. SOC + ZA did not improve survival compared to OS, suggesting that ZA as an agent did not improve survival beyond that attributed to doce.
+*** SOC + '''docetaxel improved OS by 10 months''' (median OS in SOC + doce 81 months vs. SOC 71 months, HR 0.78). SOC + ZA + doce has improved survival compared to SOC but no difference with SOC + doce. SOC + ZA did not improve survival compared to OS, suggesting that ZA as an agent did not improve survival beyond that attributed to doce.
 *** Failure-free survival, skeletal-related events, and cancer-specific survival also improved in patients receiving docetaxel.
 *** Febrile neutropenia and neutropenia were the most common adverse events in the docetaxel arm